Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab with or without tiragolumab after definitive chemoradiotherapy for unresectable esophageal squamous cell carcinoma
2020-001178-31Phase 3Active
- Sponsor
- Roche
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing tiragolumab + atezolizumab, placebo + atezolizumab and double placebo (3 arms). Primary endpoints: Progression-Free Survival and Overall Survival. Started Sep 2020; status: active.
02
Drugs
tiragolumabatezolizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2020-001178-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001178-31.